Delandistrogene Moxeparvovec Gene Therapy in Individuals with Duchenne Muscular Dystrophy Evidence in Focus
Evidence in Focus, May 2025
Read Published ArticleThis Evidence in Focus reviews the current evidence on the efficacy and safety of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) and presents clinical considerations regarding use.
Clinician Tools and Materials
Clinician Summary
Download a PDF summary of this guideline product
好色先生al Materials
Other resources related to this guideline
Patient Tools and Materials
Patient Summary
Read a summary of the key messages of this guideline product for patients and care partners.